entertainment -WSS

entertainment

author：hotspot 2025-09-29 07:35:12 - browse：246

Illustration of three connected puzzle pieces, with a woman standing near the missing/empty puzzle piece space. -- first opinion coverage from STAT — Adobe

Women have always been underrepresented in medical research. A new study reveals that not much has changed, especially when it comes to tests of cardiovascular devices.

In a paper published in JAMA Internal Medicine on Monday, researchers found that the percentage of women represented in high-risk medical device trials did not increase from 2010 to 2020. Women generally made up just 33% of participants when the team reviewed 195 trials published from 2016 to 2022. The percentages varied between devices: Women made up 46% of participants in orthopedic trials, but 29% in cardiovascular studies.

The issue isn’t new. The government has made some strides in correcting earlier missteps, like the Food and Drug Administration telling researchers in 1977 to exclude women of reproductive potential from early clinical trials. But stakeholders think agencies like the FDA could do more to incentivize the enrollment of women.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： For one rare type of lung cancer, Pfizer pill reduces progression by 81%

explore

WSS

ASCO: AstraZeneca says CAR

'Make People Better': The CRISPR babies story you probably don't know

Covid hospitalizations on the rise, Humana says

The (many) problems with a new study criticizing cancer screening

Covid hospitalizations on the rise, Humana says

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

focus

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Wikipedia

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Guidelines to prevent youth baseball injuries need more muscle

How to protect patients from sexual assault

Affirmative action in medical school literally saved lives

Medicaid rebukes states for mistakenly disenrolling children

State Dept. review finds Biden bears some blame for Afghanistan failures

House transparency, PBM reform bill gains bipartisan support

Cancer drug shortages should be causing more outrage

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

focus

AstraZeneca chief proposes a novel edit to the drug pricing bill

With trial win, GSK could get blood cancer drug back on market

Advances in CAR

A rare thyroid diagnosis led to unexpected, all

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Let's speed up science by embracing open access publishing

leisure time

hotspot

explore

focus